retatrutide gip glp-1 glucagon receptor agonist PDB-101: Molecule of the Month: Agonists Structural insights into the triple
Description
Since initiation, her hemoglobin A1c decreased from 8.6% to 5.6%, insulin therapy was discontinued, and she achieved significant weight loss, with improved liver function and laboratory parameters
About PTLabs: PTLabs is committed to supplying premium-grade research compounds with a focus on quality, consistency, and reliability
Eli Lilly reported another success in a study pitting its once-daily oral GLP-1 therapy Orforglipron against a competing type 2 DM therapy, this time AstraZeneca's SGLT2I Farxiga (Dapagliflozin)
Phase 3 development is ongoing under Eli Lilly's TRIUMPH program
Safety notes
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
